Background: In 2015, the biosimilar filgrastim EP2006 became the first biosimilar approved by the US Food and Drug Administration for commercial use in the United States, marketed as Zarxio V R (Sandoz). This phase III randomised, double-blind registration study in patients with breast cancer receiving (neo)adjuvant myelosuppressive chemotherapy (TAC; docetaxel þ doxorubicin þ cyclophosphamide) compares reference filgrastim, Neupogen V R (Amgen), with two groups receiving alternating treatment with reference and biosimilar every other cycle.
Introduction
Development of a biosimilar medicine involves a series of characterisations and comparisons carried out in a step-wise fashion to provide evidence that the biosimilar is similar to the reference product [1] . This step-wise approach includes extensive analytical comparisons of the structural and functional properties of the medicines so that clinical trials are considered confirmatory [2] ; and as a part of the totality of evidence demonstrate that the biosimilar provides equivalent clinical efficacy and safety to the reference product [3] . Regulatory bodies including the Brazilian Health Surveillance Agency (Anvisa), European Medicines Agency (EMA), Korea's Ministry of Food and Drug Safety, and the US Food and Drug Administration (FDA) have outlined strict frameworks by which comparisons between the biosimilar and reference biologic should be carried out.
The biosimilar filgrastim Zarzio V R /EP2006 was approved in Europe in 2009 and in 2015 became the first biosimilar to be approved by the FDA for commercial use in the United States, marketed as Zarxio V R /filgrastim-sndz. Once a biosimilar product such as Zarzio V R /Zarxio V R has received marketing approval, physicians are faced with decisions on best practice including how to switch between a biosimilar and a reference medicine. Reasons to consider switching may include loss of efficacy, adverse events (AEs), patient convenience, and cost [4] . However, issues such as immunogenicity of biologics may make physicians unsure when to switch [5] . In the United States, the Biologics Price Competition and Innovation Act (BPCI Act) includes an additional approval stage for a product to be designated 'interchangeable biosimilar' status, permitting unlimited switching from the reference product [4] . In the European Union (EU), recommendations regarding switching between reference products and biosimilars are the responsibility of individual Member States [6] . Although approval of a biosimilar is based on totality of evidence that confirms that clinical efficacy and safety are equivalent to the reference product, clinical data on switching may be reassuring for physicians [6] . PIONEER (NCT01519700) was a phase III pivotal confirmatory trial that compared US-licensed filgrastim (Neupogen V R , Amgen Thousand Oaks, California) with two groups who received alternating treatment with reference and biosimilar every other treatment cycle. To further evaluate the data on switching of biosimilar filgrastim (Zarzio V R /Zarxio V R /EP2006) with reference filgrastim, here we present the results of an analysis of patients included in the study who received reference filgrastim, and a combined group of patients receiving switched treatment with either reference and then biosimilar, or biosimilar and then reference.
Methods

Study design
PIONEER was a randomised, double-blind, parallel-group, multicentre study designed to compare the efficacy and safety of biosimilar filgrastim and reference filgrastim in patients with breast cancer undergoing myelosuppressive chemotherapy. Women aged !18 years with histologically proven breast cancer eligible for treatment with docetaxel 75 mg/m 2 , doxorubicin 50 mg/m 2 and cyclophosphamide 500 mg/m 2 [TAC regimen, risk of febrile neutropenia (FN): 22%-25% [7] ] were randomised 1: 1: 1: 1 into four arms. Two arms (unswitched) received only one product, biosimilar (EP2006/Zarzio V R , Sandoz) or reference (Neupogen V R , Amgen), and two arms received alternating treatments every other cycle (biosimilar then reference or vice versa over six cycles) (Figure 1 ). Filgrastim was administered (5 lg/kg body weight/day, s.c.) from day 2 of each cycle until the absolute neutrophil count (ANC) recovered to 10 Â 10 9 /l after its nadir or for a maximum of 14 days. The study has been published previously and the study design described in detail [8] . In addition to the primary objective of assessing efficacy of EP2006 compared with the reference (US-licensed) medicine, with respect to the mean duration of severe neutropenia (DSN) during cycle 1 of the neoadjuvant or adjuvant TAC regimen, a key component of the study with its four-arm design was to show that repeated switching between EP2006 and reference has no impact on efficacy, safety, or immunogenicity compared with patients continuously treated with either EP2006 or reference. The study was conducted in accordance with the Figure 1 . Study design. Four patients (one in biosimilar, one in biosimilar-reference and two in the reference group) did not receive study medication.
Declaration of Helsinki and Good Clinical Practice. Study protocols were reviewed by Independent Ethics Committees for each centre. All patients provided written informed consent.
Patients
Key inclusion criteria were Eastern Cooperative Oncology Group (ECOG) performance status 2 and adequate bone marrow function on day 1 of cycle 1 before chemotherapy. Exclusion criteria were discussed in detail in the first report of the study [8] .
End points
Since the switch occurred from cycle 2 onwards, this analysis compared pooled switched groups to the unswitched reference group for efficacy during cycles 2-6. Data are not presented here for the group who received biosimilar filgrastim continuously. End points included incidence of FN (oral temperature !38.3 C and ANC <0.5 Â 10 9 /l on the same day), incidence of infections, incidence of hospitalisations due to FN, time and depth of ANC nadir (the patient's lowest ANC in the respective chemotherapy cycle), time to ANC recovery, and ANC profile.
AEs were recorded across all cycles for the safety population (SAF: all patients who received !one dose of study medication and had !one post-baseline safety assessment) and the switched safety population (SAF-I: all patients who received !one dose of study medication after Cycle 1). Immunogenicity was also assessed.
Statistical analysis
Evaluation of non-inferiority in overall FN rates between switching and non-switching groups was based on a non-inferiority margin of 15%, in line with FDA guidance [9] . The non-inferiority margin of 15% was selected based on the fact that filgrastim treatment was known to reduce the incidence of FN by approximately 30% as compared with no granulocyte colony-stimulating factor (G-CSF) support. The non-inferiority margin of 15% was thus chosen to maintain >50% of the known effect size of filgrastim treatment.
All statistical analyses were carried out using SAS (SAS Institute, Cary, NC).
Results
Patients
A total of 218 patients were randomised to treatment in this phase III registration trial. Four patients did not receive treatment; 109 patients received switched treatment, 52 patients received reference, and 53 received filgrastim biosimilar in all cycles. Patient disposition is shown in supplementary Figure S1 , available at Annals of Oncology online. Baseline characteristics were similar between groups ( Table 1) .
Incidence of FN was 0% in the reference group versus 3.4% (n ¼ 3) in the switched group across cycles 2-6, with a difference of À3.4% [95% confidence interval (CI): À9.65% to 4.96%], showing that the switched group was non-inferior to the reference based on the predefined non-inferiority margin of À15% (supplementary Table S1 , available at Annals of Oncology online). One patient in the switched group was hospitalised due to FN in cycle 6. Infections occurred in 9.3% of patients in the switched group versus 9.9% in the reference group. There was no common pattern observed regarding the infections. Most frequent were respiratory tract infections, which were similarly distributed between the reference and switched groups and among the cycles. Depth of ANC nadir for the reference and the switched groups were similar in mean (SD) (sup plementary Table S2 , available at Annals of Oncology online). Time of ANC nadir was similar in distribution for both groups (supple  mentary Table S3 , available at Annals of Oncology online). The mean difference in time to ANC recovery (days) and the corresponding 90% CI for the reference-switching treatment groups were contained within the 61-day equivalence margin from cycles 2-6 (supplementary Table S4 , available at Annals of Oncology online). The time courses of the mean ANC for the reference and switched groups were superimposable across cycles 2-6 ( Figure 2) . Only a few patients remained on treatment from day 12 so results after this point should be interpreted with caution.
Safety results are presented for treatment-emergent (TE) AEs observed across all six cycles. The incidences and patterns of the TEAEs were similar between the reference and switched groups and, overall, were consistent with the known safety profile of filgrastim (Table 2) . TEAEs related to filgrastim were reported in 42.1% of the switched group versus 39.2% of the reference group (all cycles). No patients in either group experienced filgrastimrelated serious TEAEs. No patients experienced a TEAE that led to discontinuation of study drug. The most frequent system organ class of TEAEs with a suspected relationship to filgrastim was musculoskeletal/connective tissue disorders, reported in 39.2% of the reference group versus 35.5% of the switched group (supplementary Table S5 , available at Annals of Oncology online). This included bone pain, reported in 33.3% of the reference group versus 30.8% of the switched group. No deaths were reported in either of the two treatment groups.
No neutralising antibodies against recombinant human (rh-)-G-CSF were detected in the study.
Discussion
This analysis of the switched treatment patients from PIONEER was designed to provide additional evidence that efficacy, safety, Figure 2 . Time course of mean absolute neutrophil count (ANC) for Cycle 1 (PP-IS). n, number of assessable patients; PP-IS, Per Protocol Interchangeability Analysis Set, including all patients who completed six cycles without a major protocol deviation; SD, standard deviation. and immunogenicity are similar in patients receiving switched treatment with filgrastim (biosimilar then reference, or vice versa) compared with those receiving continuous treatment with reference. To the best of our knowledge, this is the first evidence in oncology patients to report data on switching between a reference biologic and a biosimilar. The primary analysis results from PIONEER demonstrated non-inferiority of the biosimilar to the reference (DSN in cycle: biosimilar, 1.17 6 1.11; reference: 1.20 6 1.02) since the lower boundary of the 97.5% CI for the difference was À0.26 days and thus above the predefined limit of À1 day [8] . No clinically meaningful differences were reported for any other efficacy parameters [8] . Safety results were also similar between groups. Based on this additional analysis, switching between the biosimilar and the reference or vice versa also did not show clinically meaningful differences regarding efficacy and safety, or led to increased risk of developing anti-rh-G-CSF antibodies.
The results from the analysis reported here show that for FN, the switched group was non-inferior to the reference. No clinically meaningful differences were reported for other efficacy end points including hospitalisation due to FN, time and depth of ANC nadir, and incidence of infections over all cycles. Mean ANC time courses were similar for both the reference and switched groups. The safety profile for the reference and switched groups in this study was in line with the known safety profile for the reference, with musculoskeletal/connective tissue disorders the most frequently reported AEs associated with filgrastim. A pooled analysis of the two pivotal registration trials with EP2006 showed similar efficacy and safety results [10] to findings of studies carried out for the reference product.
These results are similar to the overall results from PIONEER where comparisons included evaluating switched patients versus non-switched patients by pooling results for the two nonswitching arms (patients receiving reference for all cycles, and patients receiving biosimilar for all cycles) and for the switching arms (patients receiving biosimilar and then reference, and patients receiving reference then biosimilar). The current study excluded patients receiving biosimilars alone to provide evidence that switching would not put patients at higher risk compared with receiving reference alone, rather than compared with reference or biosimilar filgrastim alone. Biosimilar EP2006 has been well studied; in addition to the phase III registration trials, pharmacovigilance studies are underway including MONITOR G-CSF, an international, multicentre, prospective, observational, open-label study including patients at 140 centres across 12 European countries. The results to date support the efficacy and favourable safety profile of Zarzio V R in daily practice and extend the efficacy and safety data from its clinical development programme [11] [12] [13] [14] . However, other than PIONEER, there are no randomised controlled trials assessing switching between filgrastim biosimilars and reference products. A retrospective study investigated prescribing patterns of G-CSF in five Italian centres and reported that 155 (9%) of 1721 reference filgrastim users switched to biosimilar filgrastim during the first year of treatment [15] . An increase in biosimilar filgrastim use was observed over the 5-year period of the study; however, most biosimilar users were naive patients (77%). Efficacy and safety results were not reported.
Switching between biosimilar and reference medications continues to be a concern for physicians regarding biosimilars and there is a lack of consensus for best practice [16] . A recent study reported that medical specialists (rheumatologists, dermatologists, gastroenterologists, oncologists, and haematologists) in New Zealand reported positive attitudes towards biosimilars, but that they were less confident in switching between biosimilars and reference products [17] . A lack of clinical data was cited as a reason not to prescribe a biosimilar, highlighting the need for robust evidence from clinical trials and post-marketing surveillance to build physicians' confidence in switching.
Current evidence shows that the design of biosimilar switching trials varies between medicines. This likely reflects the different indications, and it is of note that most data on switching are from studies in immunology including rheumatoid arthritis. Treatment of rheumatoid arthritis is chronic and thus studies will differ from those in patients receiving G-CSF for a short period while they receive myelosuppressive chemotherapy. A recent review of switching studies in immunology suggested that studies assessing switching should include evaluation of multiple switches between the biosimilar and reference [18] . The authors also suggested that other design elements be incorporated into trials to ensure adequate sensitivity to assess switching including a sufficient treatment duration before switching, appropriate choice of endpoints, adequate sample sizes, and measurement of anti-drug antibodies. In line with these suggestions, PIONEER included multiple switches; switching at each cycle is comparable to how switches are made in real-world use; FN is an endpoint that can be grouped over cycles 2-6 to assess the effect of switching; and immunogenicity was assessed. However, a limitation is that the review [18] focused on immunology and its recommendations may not be entirely appropriate for the oncology setting of PIONEER.
No neutralising antibodies against rh-G-CSF were detected in PIONEER during switching between reference and biosimilar medicines. This is of importance since immunogenicity remains a concern for physicians regarding switching biosimilars [16] . This result is supported by data from post-marketing studies of Zarzio V R in which no anti-rh-G-CSF antibodies have been reported across the clinical programme [19] . Indeed, the available evidence for the different biosimilar filgrastim medicines available on the market suggests that immunogenicity is not a particular concern for filgrastim [2, 16, [19] [20] [21] .
No clinically meaningful differences between the reference and switched groups has implications for practice since evidence suggests considerable cost savings can be made using biosimilar filgrastim rather than reference filgrastim. A study used simulated models to estimate potential cost savings of switching patients from reference to biosimilar filgrastim in EU G5 countries [22] . The study showed that savings per cycle associated with using biosimilar filgrastim rather than reference filgrastim ranged from e785 for a 4-day regimen to e2747 for a 14-day regimen and increased as treatment duration increased [22] . This demonstrates the potential savings and improved access to therapy associated with switching from reference to biosimilar filgrastim. Our data support this approach since they suggest such a switch can be made without changes in efficacy or safety.
In conclusion, this study showed that there are no clinically meaningful differences regarding efficacy, safety or immunogenicity when switching from reference to biosimilar filgrastim/ EP2006, or vice versa, and that switching can be carried out without cause for concern.
